Background: Pulmonary hypertension is characterized by high pulmonary blood pressure, vascular remodeling, and right ventricular hypertrophy. Although recent studies suggest that an imbalance between endothelial mediators on pulmonary vasculature may contribute to the development of pulmonary hypertension, the pathogenesis is not fully understood and the treatment of pulmonary hypertension is still unresolved. Objective: The purpose of this study was to investigate whether genistein, a phytoestrogen derived from soybean, would prevent the development of monocrotaline (MCT)-induced pulmonary hypertension in rats. Hemodynamic parameters of catheterized rats and morphological feature of lungs were evaluated among MCT-treated rats receiving or not receiving genistein. Furthermore, examination of expression in endothelial nitric oxide synthase and endothelin-1 peptide level was performed. Methods: Daily supplementation with either genistein (0.2 mg/kg) or vehicle was started 2 days prior to a single-dose injection of MCT (60 mg/kg). On day 28, rats underwent catheterization, and right ventricular hypertrophy and morphological features were assessed. Furthermore, endothelial nitric oxide synthase and endothelin-1 were examined by Western blot analysis and radioimmunoassay, respectively, in homogenated lungs. Results: In rats that received daily supplementation of genistein, mean pulmonary arterial pressure was significantly reduced, whereas mean systemic arterial pressure and heart rate were unaltered compared with MCT control rats on day 28 after MCT injection. Right ventricular hypertrophy, medial wall thickness of pulmonary arteries corresponding to the terminal bronchioles, and the degree of neomuscularization of more distal arteries were less severe in genistein-treated rats. Genistein supplementation improved MCT-induced downregulation of expression of endothelial nitric oxide synthase in the lungs. However, endothelin-1 peptide levels did not differ among all groups of lungs. Conclusions: We conclude that daily supplementation of genistein potently attenuates MCT-induced pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular remodeling in rats. The underlying mechanism responsible for this effect may be partly related to the restoration of a decreased expression of endothelial nitric oxide synthase.

Keywords:
Genistein, Monocrotaline, Pulmonary hypertension, Endothelial nitric oxide synthase, Endothelin-1
1.
Demoncheaux EAG, Higenbottam TW, Kiely DG, Wong JM, Wharton S, Varcoe R, Siddons T, Spivey AC, Hall K, Gize AP: Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res 2005;42:133–136.
2.
Gianetti J, Bevilacqua S, De Caterina R: Inhaled nitric oxide: more than a selective pulmonary vasodilator. Eur J Clin Invest 2002;32:628–635.
3.
Weinberger B, Laskin DL, Heck DE, Laskin JD: The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:5–16.
4.
Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshita A: Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004;94:385–393.
5.
Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF: Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004;287:L656–L664.
6.
Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N, Yamazaki A, Ushiyama Y, Yazaki Y, Kinoshita O: Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 2003;60:692–699.
7.
Kanno S, Wu YJ, Lee PC, Billiar TR, Ho C: Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 2001;104:945–950.
8.
Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qui D, Pearl RG, Kao PN: Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002;166:1403–1408.
9.
Zhao YD, Campbell AI, Robb M, Ng D, Stewart DJ: Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res 2003;92:984–991.
10.
Filipeanu CM, Brailoiu E, Huhurez G, Slatineanu S, Baltatu O, Branisteanu DD: Multiple effects of tyrosine kinase inhibitors on vascular smooth muscle contraction. Eur J Pharmacol 1995;281:29–35.
11.
Toma C, Jensen PE, Prieto D, Hughes A, Mulvany MJ, Aalkjaer C: Effects of tyrosine kinase inhibitors on the contractility of rat mesenteric resistance arteries. Br J Pharmacol 1995;114:1266–1272.
12.
Kitayama J, Kitazono T, Ooboshi H, Ago T, Ohgami T, Fujishima M, Ibayashi S: Chronic administration of a tyrosine kinase inhibitor restores functional and morphological changes of the basilar artery during chronic hypertension. J Hypertens 2002;20:2205–2211.
13.
Squadrito F, Altavilla D, Squadrito G, Saitta A, Cucinotta D, Minutoli L, Deodato B, Ferlito M, Campo GM, Bova A, Caputi AP: Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy in rats. Cardiovasc Res 2000;45:454–462.
14.
Karamsetty MR, Klinger JR, Hill NS: Phytoestrogens restore nitric oxide-mediated relaxation in isolated pulmonary arteries from chronically hypoxic rats. J Pharmacol Exp Ther 2001;297:968–974.
15.
Mishra SK, Abbot SE, Choudhury Z, Cheng M, Khatab N, Maycock NJR, Zavery A, Aaronson PI: Endothelium-dependent relaxation of rat aorta and main pulmonary artery by phytoestrogens genistein and daidzein. Cardiovasc Res 2000;46:539–546.
16.
Nakazawa H, Hori M, Ozaki H, Karaki H: Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats. Br J Pharmacol 1999;128:1098–1104.
17.
Resta TC, Gonzales RJ, Dail WG, Sanders TC, Walker BR: Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol Heart Circ Physiol 1997;272:H806–H813.
18.
Frasch HF, Marshall C, Marshall BE: Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am J Physiol 1999;276:L304–L310.
19.
Jasmin JF, Cernacek P, Dupuis J: Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade. Clin Sci (Lond) 2003;105:647–653.
20.
Mansoor AM, Honda M, Saida K, Ishinaga Y, Kuramochi T, Maeda A, Takabatake T, Mitsui Y: Endothelin induced collagen remodeling in experimental pulmonary hypertension. Biochem Biophys Res Commun 1995;215:981–986.
21.
Mathew R, Zeballos GA, Tun H, Gewitz MH: Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res 1995;30:739–746.
22.
Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K: Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993;73:887–897.
23.
Sasaki S, Asano M, Ukai T, Nomura N, Maruyama K, Manabe T, Mishima A: Nitric oxide formation and plasma L-arginine levels in pulmonary hypertensive rats. Respir Med 2004;98:205–212.
24.
Suhara H, Sawa Y, Fukushima N, Kagisaki K, Yokoyama C, Tanabe T, Ohtake S, Matsuda H: Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats. J Thorac Cardiovasc Surg 2002;123:855–861.
25.
Takahashi T, Kanda T, Inoue M, Sumino H, Kobayashi I, Iwamoto A, Nagai R: Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Life Sci 1998;63:PL137–PL143.
26.
Hanasato N, Oka M, Muramatsu M, Nishino M, Adachi H, Fukuchi Y: E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1999;277:L225–L232.
27.
Naruse M, Naruse K, Kurimoto F, Horiuchi J, Tsuchiya K, Kawana M, Kato Y, Zeng ZP, Sakurai H, Demura H, Shizume K: Radioimmunoassay for endothelin and immunoreactive endothelin in culture medium of bovine endothelial cells. Biochem Biophys Res Commun 1989;160:662–668.
28.
Polkowski K, Mazurek AP: Biological properties of genistein. A review of in vitro and in vivo data. Acta Pol Pharm 2000;57:135–155.
29.
Armitage M, Nooney J, Evans S: Recent concerns surrounding HRT. Clin Endocrinol (Oxf) 2003;59:145–155.
30.
Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ: Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 1999;33:177–182.
31.
Pan W, Ikeda K, Takebe M, Yamori Y: Genistein, daidzein and glycitein inhibit growth and DNA synthesis of aortic smooth muscle cells from stroke-prone spontaneously hypertensive rats. J Nutr 2001;131:1154–1158.
32.
Tsuda Y, Okazaki M, Uezono Y, Osajima A, Kato H, Okuda H, Oishi Y, Yashiro A, Nakashima Y: Activation of extracellular signal-regulated kinase is essential for pressure-induced proliferation of vascular smooth muscle cells. Eur J Pharmacol 2002;446:15–24.
33.
Squadrito F, Altavilla D, Crisafulli A, Cucinotta D, Morabito N, D’Anna R, Corrado F, Ruggeri P, Frisina N, Squadrito G: Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med 2003;114:470–476.
34.
Tyler RC, Muramatsu M, Abman SH, Stelzner TJ, Rodman DM, Bloch KD, McMurtry IF: Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 1999;276:L297–L303.
35.
Laplante MA, Wu R, El Midaoui A, de Champlain J: NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat’s vascular smooth muscle cells. J Hypertens 2003;21:927–936.
36.
Mathew R, Yuan N, Rosenfeld L, Gewitz MH, Kumar A: Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs. Heart Dis 2002;4:152–158.
37.
Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732–1739.
38.
Çelik G, Karabiyikoglu G: Local and peripheral plasma endothelin-1 in pulmonary hypertension secondary to chronic obstructive pulmonary disease. Respiration 1998;65:289–294.
39.
Hill NS, Warburton RR, Pietras L, Klinger JR: Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 1997;83:1209–1215.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.